{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-206235","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.568977+00:00","generated_at":"2026-06-12T02:45:52.034513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cytek Q2 revenue up 24% to $49.7M; net loss widens to $4.4M","bullets":["Revenue $49.7M (+24% YoY); organic revenue $41.5M (+3%) excl. $8.2M from Luminex acquisition.","Gross margin 57% vs 61% YoY; adjusted gross margin 60% vs 64%.","Operating loss $9.1M (vs $0.9M loss Q2 2022); net loss $4.4M (vs $0.7M).","Adjusted EBITDA $1.5M vs $4.8M prior year; cash $298.8M.","Shipped 100th Cytek Aurora Cell Sorter; FY2023 revenue guidance reaffirmed at $205M-$220M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-206235","json":"https://secwatch.observer/filing/0001193125-23-206235.json","markdown":"https://secwatch.observer/filing/0001193125-23-206235.md","text":"https://secwatch.observer/filing/0001193125-23-206235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/0001193125-23-206235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/d440092d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:45:52.034513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e55a506fa36d9fcc20bede48df8ee01987e1cb78","claim":"Cytek Biosciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $49.7 million, net income $4.4 million. Guidance reaffirmed.","evidence_excerpt":"(“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 • Total revenue on a non-GAAP constant currency basis was $50.0 million • Organic revenue for Cytek’s existing product","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/0001193125-23-206235-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$49.7 million"},{"label":"Net income","value":"$4.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}